{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:48:33Z","timestamp":1770479313634,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.bcmd.2009.09.006","type":"journal-article","created":{"date-parts":[[2009,10,5]],"date-time":"2009-10-05T09:34:35Z","timestamp":1254735275000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease"],"prefix":"10.1016","volume":"44","author":[{"given":"Carla E.M.","family":"Hollak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"vom Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yossi","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Collin-Histed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Deegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"van Dussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Michelakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hrebicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"di Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Pocovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Clara","family":"Sa Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tylki-Szymanska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2009.09.006_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides, II: evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2009.09.006_bib2","first-page":"97","article-title":"Short communications: a deficiency of glucocerebrosidase in Gaucher's disease","author":"Patrick","year":"1955","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcmd.2009.09.006_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2009.09.006_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","article-title":"Gaucher's disease: clinical features and natural history","volume":"10","author":"Cox","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.bcmd.2009.09.006_bib5","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3636","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.bcmd.2009.09.006_bib6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency \u2014 macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2009.09.006_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"issue":"8963","key":"10.1016\/j.bcmd.2009.09.006_bib8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(95)91038-7","article-title":"Replacement therapy with imiglucerase for type 1 Gaucher's disease","volume":"345","author":"Zimran","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcmd.2009.09.006_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated(R) human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.bcmd.2009.09.006_bib10","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme \u2014 a preclinical and phase I investigation","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcmd.2009.09.006_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2009.09.006_bib12","unstructured":"European Medicines Agency (EMEA). PRESS RELEASE. Supply shortages of Cerezyme and Fabrazyme \u2014 priority access for patients most in need of treatment recommended. 25-6-2009."},{"key":"10.1016\/j.bcmd.2009.09.006_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.2000.02177.x","article-title":"Withdrawal of enzyme replacement therapy in Gaucher's disease","volume":"110","author":"Elstein","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2009.09.006_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1046\/j.1365-2141.2001.02821-9.x","article-title":"Clinical monitoring after cessation of enzyme replacement therapy in M","volume":"113","author":"vom Dahl","year":"2001","journal-title":"Gaucher. Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2009.09.006_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1046\/j.1365-2141.2001.02821-13.x","article-title":"Effects of imilglucerase withdrawal on an adult with Gaucher disease","volume":"113","author":"Schwartz","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2009.09.006_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00125817-200211000-00005","article-title":"Cessation of enzyme replacement therapy in Gaucher disease","volume":"4","author":"Grinzaid","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2009.09.006_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1034\/j.1600-0609.2003.00010.x","article-title":"Rebound hepatosplenomegaly in type 1 Gaucher disease","volume":"70","author":"Toth","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2009.09.006_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","article-title":"Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease","volume":"151","author":"Drelichman","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcmd.2009.09.006_bib19","unstructured":"U.S. Cerezyme Stakeholders Working Group. Revised Guidance to the U.S. Gaucher Community: Management of Cerezyme\u00ae (imiglucerase for injection) Supply. 10-8-2009."},{"key":"10.1016\/j.bcmd.2009.09.006_bib20","unstructured":"European Medicines Agency (EMEA). Questions and answers on the shortages of Cerezyme and Fabrazyme. 14-8-2009."},{"key":"10.1016\/j.bcmd.2009.09.006_bib21","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","article-title":"Individualised low-dose alglucerase therapy for type 1 Gaucher's disease","volume":"345","author":"Hollak","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2009.09.006_bib22","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2009.09.006_bib23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979609001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979609001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:26:47Z","timestamp":1761049607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979609001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1079979609001739"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2009.09.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2009.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}